Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple wash may prevent Post-Surgery bruising and bleeding

NCT ID NCT05441592

Prevention Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether applying tranexamic acid (TXA) directly into the surgical wound during breast reduction or gender-affirming mastectomy could prevent hematomas—painful collections of blood under the skin. 107 adults participated. The goal was to see if this simple, low-cost step could reduce the need for additional procedures to drain blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

107 people

The number who actually took part.

Started

Aug 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing bilateral breast reduction or bilateral gender-affirming mastectomy * For patients undergoing bilateral breast reduction, any skin incision pattern or pedicle is acceptable. * For patients undergoing bilateral gender-affirming mastectomy, any skin incision and mastectomy type is acceptable Exclusion Criteria: * Active thromboembolic disease or history of intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion * Current use of systemic anticoagulation * Hypersensitivity to tranexamic acid * Concomitant use of combined hormonal contraceptives * Use of factor IX complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acid * History of acquired defective color vision * History of subarachnoid hemorrhage * Pregnancy * History of renal impairment or serum Creatinine \>1.5 milligrams per deciliter (mg/dL)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematoma postoperative are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematoma postoperative

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.